Anna-Karin Haylock
Physician at Department of Surgical Sciences; Otorhinolaryngology and Head and Neck Surgery
- E-mail:
- anna-karin.haylock@uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 78/79
751 85 Uppsala - Postal address:
- Akademiska sjukhuset, ingång 78/79
751 85 Uppsala
Publications
Recent publications
Part of Clinical Nutrition ESPEN, p. 149-155, 2020
- DOI for Mapping impact factors leading to the GLIM diagnosis of malnutrition in patients with head and neck cancer
- Download full text (pdf) of Mapping impact factors leading to the GLIM diagnosis of malnutrition in patients with head and neck cancer
Part of International Journal of Oncology, p. 1875-1885, 2018
- DOI for Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
- Download full text (pdf) of Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
Part of Oncotarget, p. 65152-65170, 2017
- DOI for Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
- Download full text (pdf) of Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
Targeting molecules for diagnostics of Head and Neck squamous cell carcinoma
2017
A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties
Part of Nuclear Medicine and Biology, p. 12-18, 2016
All publications
Articles in journal
Part of Clinical Nutrition ESPEN, p. 149-155, 2020
- DOI for Mapping impact factors leading to the GLIM diagnosis of malnutrition in patients with head and neck cancer
- Download full text (pdf) of Mapping impact factors leading to the GLIM diagnosis of malnutrition in patients with head and neck cancer
Part of International Journal of Oncology, p. 1875-1885, 2018
- DOI for Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
- Download full text (pdf) of Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
Part of Oncotarget, p. 65152-65170, 2017
- DOI for Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
- Download full text (pdf) of Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers
A real-time in vitro assay as a potential predictor of in vivo tumor imaging properties
Part of Nuclear Medicine and Biology, p. 12-18, 2016
Part of International journal of oncology, p. 461-470, 2016
- DOI for Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma
- Download full text (pdf) of Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma
A real-time in vitro assay as a potential predictor of in vivo tumour imaging properties
Part of European Journal of Nuclear Medicine and Molecular Imaging, 2015
Part of EJNMMI Research, 2014
- DOI for In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study
- Download full text (pdf) of In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study
Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014
Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014
Part of European Journal of Nuclear Medicine and Molecular Imaging, 2013
A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio
Part of International Journal of Oncology, p. 1525-1532, 2012
Part of Cancer Biotherapy and Radiopharmaceuticals, p. 593-601, 2011